NCT02596256Unknown2 期
Apatinib Plus Docetaxel Versus Docetaxel as Second-line Treatment in Advanced Gastric Cancer Stage II Randomized Controlled Clinical Studies
Chinese PLA General Hospital1 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2016年4月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 80
- 试验地点
- 1
- 主要终点
- Progression free survival
研究概览
简要总结
Apatinib plus docetaxel versus docetaxel as second-line treatment in advanced gastric cancer.
详细描述
This trial investigated the safety and efficacy of apatinib plus docetaxel, as a treatment option for heavily pretreated patients with advanced gastric cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age: more than 18 years old, male or female;
- •Pathologically diagnosed with advanced gastric cancer (including adenocarcinoma of the gastroesophageal junction) with measurable metastases outside the stomach (measuring ≥ 10mm on spiral computed tomography(CT) scan, satisfying the criteria in Response Evaluation Criteria In Solid Tumors (RECIST) 1.1);
- •Failure of prior therapy (during or after treatment) in patients who have received at first line chemotherapy regimens(platinum - based regimens);
- •Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0-1;
- •Major organ function has to meet the following criteria; (1) For results of blood routine test and biochemical tests:
- •Hemoglobin (HB) ≥ 80g / L,
- •ANC ≥ 1.5 × 109 / L,
- •PLT ≥ 90 × 109 / L,
- •ALT and AST ≤ 2.5 × ULN, liver metastases, if any, the ALT and AST≤5 × ULN,
- •Bilirubin ≤ 1.5 times the upper limit of normal (ULN),
- •Serum creatinine ≤ 1.5 times the upper limit of normal (ULN),
- •Serum albumin ≥ 30g / L;
- •An expected survival of ≥ 3 months;
- •Pregnancy test (serum or urine) has to be performed for woman of childbearing age within 7 days before enrolment and the test result must be negative. They shall take appropriate methods for contraception during the study until the 8th week post the last administration of study drug. For men, (previous surgical sterilization accepted), shall agree to take appropriate methods of contraception during the study until the 8th week post the last administration of study drug;
- •Patient has to voluntarily join the study and sign the Informed Consent Form for the study.
排除标准
- •Confirmed that apatinib and/or its accessories allergy;
- •Subjects with poor-controlled arterial hypertension (systolic blood pressure> 140 mmHg and diastolic blood pressure > 90 mm Hg) despite standard medical management; Coronary heart disease greater than Class Ⅰ; Ⅰ-level arrhythmia (including QT interval prolongation, for man ≥ 450 ms, for woman ≥ 470 ms) together with Class Ⅰ cardiac dysfunction; Patients with positive urinary protein;
- •Factors that could have an effect on oral medication (such as inability to swallow, chronic diarrhea and intestinal obstruction);
- •Subjects with high gastrointestinal bleeding risk, including the following conditions: local active ulcer lesions with positive fecal occult blood test (++); history of black stool, or vomiting blood in the past 2 months;unresected primary lesion in stomach with positive fecal occult blood test (+), ulcerated gastric carcinoma with massive alimentary tract bleeding risk judged by PIs based on gastric endoscopy result;
- •Abnormal Coagulation (INR>1.5、APTT>1.5 UNL), with tendency of bleed;
- •Associated with CNS (central nervous system) metastases;
- •Pregnant or lactating women;
- •Pts with other malignant tumor within 5 years;
- •With psychotropic drug abuse history and can't get rid of or mental disorder patients;
- •Participated in other clinical trials within 4 weeks;
- •Pts received VEGFR inhibitor treatment(i.e. sorafenib, sunitinib);
- •Any other condition that might place the patient at undue risk or preclude a patient from completing the study;
- •Other conditions regimented at investigators' discretion.
研究组 & 干预措施
control group
Experimental
Apatinib Mesylate Tablets (500 mg qd p.o.) and Docetaxel (60mg/m2 i.v. d1 q21d)
干预措施: Apatinib (Drug)
control group
Experimental
Apatinib Mesylate Tablets (500 mg qd p.o.) and Docetaxel (60mg/m2 i.v. d1 q21d)
干预措施: Docetaxel (Drug)
contrast group
Active Comparator
Docetaxel (60mg/m2, i.v. d1 q21d)
干预措施: Docetaxel (Drug)
结局指标
主要结局
Progression free survival
时间窗: 6 months
次要结局
未报告次要终点
研究者
Dai, Guanghai
Department Director
Chinese PLA General Hospital
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Dovitinib Plus Docetaxel in Gastric CancerGastric CancerNCT01921673Asan Medical Center14
已完成
2 期
Docetaxel and Irinotecan in Gastric CancerChemotherapy EffectGastric CancerStomach CancerNCT04770623Menoufia University32
已完成
2 期
Docetaxel and Epirubicin in Advanced Gastric CancerStomach NeoplasmsNCT00375999Yonsei University34
Unknown
2 期
MetronomIc CApecitabine and DOcetaxel as Second-line Chemotherapy for Advanced Gastric CancerGastric AdenocarcinomaGastroesophageal Junction AdenocarcinomaNCT02007148International Group of Endovascular Oncology51
已完成
2 期
Chemotherapy Combined With Apatinib and PD-1 AntibodyGastric CancerNCT05025033Tianjin Medical University Cancer Institute and Hospital30